A5101774203- Inflammatory Bowel Disease
- Microscopic Colitis
- Immune Cell Function and Interaction
- Immunodeficiency and Autoimmune Disorders
- T-cell and B-cell Immunology
- Autoimmune and Inflammatory Disorders
- Celiac Disease Research and Management
- Chemokine receptors and signaling
- Helicobacter pylori-related gastroenterology studies
- Immunotherapy and Immune Responses
- Eosinophilic Esophagitis
- Infections and bacterial resistance
- Acute Lymphoblastic Leukemia research
- IL-33, ST2, and ILC Pathways
- Gastrointestinal Bleeding Diagnosis and Treatment
- Kruppel-like factors research
- Liver Diseases and Immunity
- Gastrointestinal disorders and treatments
- Diverticular Disease and Complications
- Genetic Associations and Epidemiology
- Immune Response and Inflammation
- Streptococcal Infections and Treatments
- Systemic Lupus Erythematosus Research
- Mycobacterium research and diagnosis
- Chronic Lymphocytic Leukemia Research
Medical University of Sofia
2023-2025
Karolinska Institutet
2023-2024
Mayo Clinic
2013-2023
WinnMed
2013-2021
Princess Royal Maternity Hospital
2020
Mayo Clinic in Arizona
2014-2019
Queen Elizabeth University Hospital
2018
AstraZeneca (United Kingdom)
2016
University of Crete
2010-2012
Crete University Press
2011
Abstract Chemokines play an important role in the migration of leukocytes at sites inflammation, and some constitutively expressed chemokines may direct lymphocyte trafficking within lymphoid organs peripheral tissues. Thymus-expressed chemokine (TECK or Ckβ-15/CCL25), which signals through receptor CCR9, is thymus small intestine but not colon, chemoattracts a fraction PBLs that coexpress integrin α4β7. Here we show TECK human bowel colon by endothelial cells subset intestinal crypts lamina...
BACKGROUND Patients with chronic, immune-mediated conditions such as inflammatory bowel disease (IBD) are often treated long-term immunosuppressive therapies, potentially increasing their risk of developing an infection. Empiric data suggest that vaccines underutilized in immunocompromised patients, despite published guidelines recommending use. We aimed to assess exposure and immunization status among patients receiving care IBD specialty clinic. METHODS completed a self-administered,...
We identified 91 cases of bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia in a prospective, multicenter observational study. The patients were highly compromised; the majority had an underlying malignancy, received immunosuppressive therapy, and indwelling venous catheters. Although 94% antimicrobial agent which blood isolate was susceptible, mortality among these 14 days after onset 21%. Mortality significantly correlated with presence hematologic malignancy or neutropenia...
CD4+CD25+ regulatory T cells (TR) can prevent or treat experimental murine colitis but little is known about their potential role in human inflammatory bowel disease (IBD). FOXP3 a transcription factor that plays critical the development and function of TR. The aim this study was to examine presence functional characteristics TR colonic lymphoid tissues patients with ulcerative (UC).FOXP3 expression assessed by flow cytometry, immunohistochemistry, reverse-transcriptase polymerase chain...
Although infliximab is highly effective in the treatment of Crohn's disease (CD), attenuated response to may develop over time a subgroup patients. The aim our study was examine safety and efficacy adalimumab (D2E7), fully humanized anti-TNF-alpha Ab, CD patients who had experienced an infliximab.Fifteen with active were treated 6-month period. Patients, received loading dose 80 mg subcutaneously followed by 40 every 2 wk. clinical classified as complete response, partial or nonresponse.Two...
Since infliximab has been approved for treatment of patients with refractory ulcerative colitis, surgeons will be increasingly faced operating on who have failed therapy this potent immunosuppressant. This study was designed to compare short-term complications in colitis were treated and without before colectomy.The charts undergoing ileal pouch-anal anastomosis or subtotal colectomy during the five-year period ending October 2005 reviewed. Postoperative medical surgical assessed.Seventeen...
Abstract TL1A, a recently described TNF-like cytokine that interacts with DR3, costimulates T cells and augments anti-CD3 plus anti-CD28 IFN-γ production. In the current study we show TL1A or an agonistic anti-DR3 mAb synergize IL-12/IL-18 to augment production in human peripheral blood NK cells. also enhanced by stimulated CD56+ When expressed as fold change, synergistic effect of on cytokine-induced was more pronounced CD4+ CD8+ than Intracellular staining showed significantly both...
Abstract The TNF-like cytokine TL1A augments IFN-γ production by anti-CD3 plus anti-CD28 and IL-12/IL-18-stimulated peripheral blood (PB) T cells. However, only a small subset of PB cells respond to stimulation with production. CCR9+ represent circulating mucosal cell characteristics Th1/Tr1 profile. In the current study, we show that enhanced TCR- or CD2/CD28-stimulated CCR9+CD4+ had most pronounced effect on augmenting IL-12/IL-18-primed both percentage mean fluorescence intensity in as...